Sanuwave Health, Inc. · NASDAQ:SNWV
Sanuwave Health — Q1 2025 Earnings Presentation
8 slides from Sanuwave Health's earnings presentation, May 9, 2025
Slide 1: Q1 FY2025
(6) SANUWAVE Wound Care Technologies Q1 FY2025 May 9, 2025
Slide 2: Live Presentation Participant Dial-in Information
Live Presentation Friday, May 9, 2025, 8:30 AM (ET) Participant Dial-in Information Toll Free: 1-800-245-3047 Toll/International: 1-203-518-9765 Conference ID: SANUWAVE OR click the link for instant telephone access to the event. https://viavid.webcasts.com/starthere.jsp?ei=1714486&tp_key=88406b4795
Slide 3: Forward Looking Statements and Non-GAAP Financial Measures
3 Forward Looking Statements and Non-GAAP Financial Measures Forward-Looking Statements This presentation may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectati
Slide 4: Financials Q1 2025
4 Financials Q1 2025 Consistent topline growth while managing operating costs. (in millions) Q1 2025 Q1 2024 YoY Revenue $9.3 $5.8 + 61% Gross Profit $7.4 $4.2 + 76% Gross Margin 79.0% 72.6% +642 bp Operating Expense $6.4* $5.3 +21% Revenue Gross Profit Operating Income (Loss) Operating Income $1.0
Slide 5: Improved operational results
5 Improved operational results See Non-GAAP Financial Measures disclosure included on slide 3
Slide 6: Growing UltraMist Systems & Consumables Sales
6 Growing UltraMist Systems & Consumables Sales Continuous UltraMIST revenue growth in 2024 and strong year on year growth in seasonally slower Q1 2025. $7.0 + 43% yoy • 1,145 systems in the field at $6.0 - 2% seq end of Q1 2025 +145% yoy • In Q1 2025: 98 systems sold $5.0 -20% seq (vs 43 in Q1 2024
Slide 7: Q2 and FY 2025 Revenue Guidance
7 Q2 and FY 2025 Revenue Guidance Q2 2025 FY 2025 REVENUE GROWTH REVENUE TARGET $48-50 million +40-50% (+47-53%) vs vs Q2 2024 REVENUE FY 2024 REVENUE of $7.16 million of $32.6 million
Slide 8: Summary
8 Summary Wound care is undergoing a payor led shift to evidence based medicine and reimbursement. This has aligned incentives for patients, payors, and providers. SANUWAVE is in a prime position to benefit: ▪ Approved products protected by strong IP ▪ Strong existing reimbursement with room to impr